Search Results

Drug Development

Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association 2024 Hybrid Congress

Wugen, Inc. announces positive Phase 2 results for the company’s investigational anti-CD7 CAR-T therapy, WU-CART-007, in patients with relapsed/refractory t-cell acute lymphoblastic leukemia/lymphoma.

June 14, 2024

·

6 min read

BioCapital

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

MaxCyte, Inc. and Wugen, Inc. announced the signing of a strategic platform license.

January 30, 2024

·

4 min read

BioMidwest

Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies

Cellipont Bioservices and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the signing of an agreement for the manufacturing of their CAR-T cell therapies.

March 14, 2024

·

2 min read

BioMidwest

Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June

Wugen today announced receipt of two new regulatory designations for its investigational CAR-T cell therapy, WU-CART-007, that it anticipates will expedite regulatory reviews on two continents.

May 20, 2024

·

5 min read

Business

Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial OfficerDr. Vendola Brings Deep, Hands-On Industry Strategy, Operational and Financial Expertise to the Role

Wugen, Inc. announced the appointment of Keith Vendola, M.D., M.B.A., as chief financial officer, effective October 2023.

January 3, 2024

·

4 min read

Drug Development

Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting

Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today shared the latest data from its ongoing Phase 1/2 dose escalation study of WU-CART-007.

December 11, 2023

·

5 min read

Drug Development

Wugen to Present New Clinical Data for WU-CART-007 and Preclinical Data for WU-NK-101, Two Investigational Allogeneic Cell Therapies for Challenging Hematologic Cancers, at American Society of Hematology Annual Meeting & Exposition

Wugen, Inc. will be presenting four abstracts, now available online, at the American Society of Hematology Annual Meeting and Exposition Dec. 9-12.

November 2, 2023

·

5 min read

BioMidwest

Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress

Wugen, Inc. today announced an oral presentation and an onsite poster presentation highlighting data from Wugen’s WU-NK-101 and WU-CART-007 programs at the European Hematology Association (EHA) 2023 Congress, taking place from June 8 – 11, 2023 in Frankfurt, Germany.

May 11, 2023

·

3 min read

Business

Wugen Announces CEO Transition

Wugen, Inc. today announced that Kumar Srinivasan Ph.D., M.B.A., has been appointed President and Chief Executive Officer, effective March 13, 2023.

March 21, 2023

·

3 min read

Business

Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors

Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, announced the appointment of industry veteran Mark Alles as Chair of the Board of Directors.

May 10, 2023

·

3 min read